← Back to Screener
Traws Pharma, Inc. Common Stock (TRAW)
Price$1.39
Favorite Metrics
Price vs S&P 500 (26W)-67.22%
Price vs S&P 500 (4W)-51.08%
Market Capitalization$14.12M
All Metrics
Book Value / Share (Quarterly)$0.64
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)0.00%
Cash Flow / Share (Quarterly)$-2.72
Price vs S&P 500 (YTD)6.48%
Net Profit Margin (TTM)-616.78%
EPS (TTM)$-7.37
10-Day Avg Trading Volume0.32M
EPS Excl Extra (TTM)$-7.37
EPS (Annual)$-107.25
ROI (Annual)-177.55%
Cash / Share (Quarterly)$0.90
ROA (Last FY)-667.11%
Revenue Growth TTM (YoY)1159.29%
EBITD / Share (TTM)$-2.15
Operating Margin (TTM)-698.31%
Cash Flow / Share (Annual)$-8.16
P/B Ratio3.11x
P/B Ratio (Quarterly)2.90x
Net Income / Employee (Annual)$-24
EV / Revenue (TTM)2.65x
ROA (TTM)-74.24%
EPS Incl Extra (Annual)$-107.25
Current Ratio (Annual)2.16x
Quick Ratio (Quarterly)1.08x
3-Month Avg Trading Volume0.25M
52-Week Price Return-37.19%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.28
P/S Ratio (Annual)62.47x
Asset Turnover (Annual)0.01x
52-Week High$3.27
EPS Excl Extra (Annual)$-107.25
26-Week Price Return-58.47%
Quick Ratio (Annual)2.02x
13-Week Price Return-29.38%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.22x
Enterprise Value$7.699
Asset Turnover (TTM)0.17x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-73682.74%
Cash / Share (Annual)$5.84
3-Month Return Std Dev130.05%
Net Income / Employee (TTM)$-2
ROE (Last FY)-177.55%
EPS Basic Excl Extra (Annual)$-107.25
Receivables Turnover (TTM)1.38x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-7.37
Receivables Turnover (Annual)0.25x
ROI (TTM)265.00%
P/S Ratio (TTM)4.86x
Revenue / Share (Annual)$0.15
Forward P/E2.54x
Price vs S&P 500 (52W)-72.28%
Year-to-Date Return10.62%
5-Day Price Return-22.36%
EPS Normalized (Annual)$-107.25
Net Profit Margin (Annual)-73682.74%
Month-to-Date Return-31.69%
EBITD / Share (Annual)$-107.57
Operating Margin (Annual)-62997.35%
EPS Basic Excl Extra (TTM)$-7.37
P/TBV (Quarterly)6.68x
Pretax Margin (TTM)-616.78%
Price vs S&P 500 (13W)-32.24%
Beta1.43x
Revenue / Share (TTM)$0.32
ROE (TTM)265.00%
52-Week Low$0.97
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TRAWTraws Pharma, Inc. Common Stock | 4.86x | 1159.29% | — | — | $1.39 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Traws Pharma is a clinical-stage biopharmaceutical company developing antiviral therapies for respiratory viral diseases, with a focus on resistant strains. The company is advancing three product candidates: Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.